Description
Kryxana™ is an authorized generic of Kisqali® used in combination with other drugs for the treatment of advanced or metastatic breast cancer whose cells are hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-).
Package Size : 21 Tablets
Active Ingredient : Ribociclib 200 MG
Manufactured by Novartis AG®
Product of Singapore